138 related articles for article (PubMed ID: 19065700)
1. Adalimumab in juvenile rheumatoid arthritis.
de Vries MK; van der Horst-Bruinsma IE; Wolbink GJ
N Engl J Med; 2008 Dec; 359(23):2496; author reply 2496-7. PubMed ID: 19065700
[No Abstract] [Full Text] [Related]
2. Adalimumab in juvenile rheumatoid arthritis.
Taddio A; Marchetti F
N Engl J Med; 2008 Dec; 359(23):2495-6; author reply 2496-7. PubMed ID: 19065749
[No Abstract] [Full Text] [Related]
3. Adalimumab in juvenile rheumatoid arthritis.
Sfriso P; Ravaioli F
N Engl J Med; 2008 Dec; 359(23):2495; author reply 2496-7. PubMed ID: 19052133
[No Abstract] [Full Text] [Related]
4. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
Lovell DJ; Ruperto N; Goodman S; Reiff A; Jung L; Jarosova K; Nemcova D; Mouy R; Sandborg C; Bohnsack J; Elewaut D; Foeldvari I; Gerloni V; Rovensky J; Minden K; Vehe RK; Weiner LW; Horneff G; Huppertz HI; Olson NY; Medich JR; Carcereri-De-Prati R; McIlraith MJ; Giannini EH; Martini A; ;
N Engl J Med; 2008 Aug; 359(8):810-20. PubMed ID: 18716298
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor blockers in rheumatoid arthritis.
Pisetsky DS
N Engl J Med; 2000 Mar; 342(11):810-1. PubMed ID: 10717018
[No Abstract] [Full Text] [Related]
6. Emerging therapies in juvenile rheumatoid/idiopathic arthritis.
Passo M
Curr Probl Pediatr Adolesc Health Care; 2006 Mar; 36(3):97-103. PubMed ID: 16473286
[No Abstract] [Full Text] [Related]
7. New treatments for juvenile idiopathic arthritis.
Hashkes PJ; Friedland O; Uziel Y
Isr Med Assoc J; 2002 Jan; 4(1):39-43. PubMed ID: 11802310
[No Abstract] [Full Text] [Related]
8. Adalimumab for rheumatoid arthritis?
Ebell M; Kripke C
Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
[No Abstract] [Full Text] [Related]
9. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
10. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease.
Sharma SM; Ramanan AV; Riley P; Dick AD
Ann Rheum Dis; 2007 Jun; 66(6):840-1. PubMed ID: 17170050
[No Abstract] [Full Text] [Related]
11. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
[TBL] [Abstract][Full Text] [Related]
12. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
Nagashima T; Minota S
J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
[No Abstract] [Full Text] [Related]
13. [New treatments for rheumatoid arthritis].
Girault V; Flipo RM
Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
[No Abstract] [Full Text] [Related]
14. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
Russo RA; Katsicas MM
J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab therapy in rheumatoid arthritis.
Keystone E; Haraoui B
Rheum Dis Clin North Am; 2004 May; 30(2):349-64, vii. PubMed ID: 15172045
[TBL] [Abstract][Full Text] [Related]
16. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment.
Bartelds GM; Wolbink GJ; Stapel S; Aarden L; Lems WF; Dijkmans BA; Nurmohamed MT
Ann Rheum Dis; 2006 Sep; 65(9):1249-50. PubMed ID: 16905585
[No Abstract] [Full Text] [Related]
17. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.
van Kuijk AW; de Groot M; Stapel SO; Dijkmans BA; Wolbink GJ; Tak PP
Ann Rheum Dis; 2010 Mar; 69(3):624-5. PubMed ID: 20223840
[No Abstract] [Full Text] [Related]
18. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Wolbink GJ; de Vries N; Tak PP; Dijkmans BA; Crusius JB; van der Horst-Bruinsma IE
Arthritis Rheum; 2009 Aug; 60(8):2541-2. PubMed ID: 19644871
[No Abstract] [Full Text] [Related]
19. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
de Vries MK; Brouwer E; van der Horst-Bruinsma IE; Spoorenberg A; van Denderen JC; Jamnitski A; Nurmohamed MT; Dijkmans BA; Aarden LA; Wolbink GJ
Ann Rheum Dis; 2009 Nov; 68(11):1787-8. PubMed ID: 19822712
[No Abstract] [Full Text] [Related]
20. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
